deltatrials
Terminated NA INTERVENTIONAL 1-arm NCT03730571

The AbsorbaSeal Vascular Closure Device Trial

Prospective, Multi-center, Non-Randomized Controlled Trial of Vascular Closure Using the AbsorbaSeal 6 French Vascular Closure Device

Sponsor: CyndRx, LLC

Updated 7 times since 2018 Last updated: Sep 7, 2021 Started: Aug 16, 2017 Primary completion: Apr 11, 2019 Completion: Apr 11, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Insufficient closure

Listed as NCT03730571, this NA trial focuses on Peripheral Arterial Disease and remains terminated or withdrawn. Sponsored by CyndRx, LLC, it has been updated 7 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Dec 2018 – ~Oct 2020 · 22 months · monthly snapshotRecruiting~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshotUnknown Status~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshotUnknown Status~Feb 2021 – ~Oct 2021 · 8 months · monthly snapshotTerminated~Oct 2021 – ~Jul 2024 · 33 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

7 versions recorded
  1. Sep 2024 — Present [monthly]

    Terminated NA

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated NA

  3. Oct 2021 — Jul 2024 [monthly]

    Terminated NA

  4. Feb 2021 — Oct 2021 [monthly]

    Terminated NA

    Status: Unknown StatusTerminated

  5. Jan 2021 — Feb 2021 [monthly]

    Unknown Status NA

Show 2 earlier versions
  1. Oct 2020 — Jan 2021 [monthly]

    Unknown Status NA

    Status: RecruitingUnknown Status

  2. Dec 2018 — Oct 2020 [monthly]

    Recruiting NA

    First recorded

Aug 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CyndRx, LLC
  • ID3 Medical
Data source: ID3 Medical

For direct contact, visit the study record on ClinicalTrials.gov .